Theratechnologies Inc. (THTX)

Market Cap	80.20M
Revenue (ttm)	59.06M
Net Income (ttm)	-21.58M
Shares Out	49.20M
EPS (ttm)	-0.91
PE Ratio	n/a
Forward PE	55.87
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,491
Open	1.56
Previous Close	1.59
Day's Range	1.55 - 1.67
52-Week Range	0.88 - 5.96
Beta	1.30
Analysts	Buy
Price Target	18.67 (+1,045.4%)
Earnings Date	Sep 26, 2023

About THTX

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, a recombinant humanized monoclonal antibody, which is an injection for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulatio...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1993
• Employees: 144
• Stock Exchange: NASDAQ
• Ticker Symbol: THTX

Financial Performance

In 2022, THTX's revenue was 80.06 million, an increase of 14.66% compared to the previous year's 69.82 million. Losses were -47.24 million, 48.9% more than in 2021.

Financial numbers in CAD

Analyst Forecast

According to 3 analysts, the average rating for THTX stock is "Buy." The 12-month stock price forecast is $18.67, which is an increase of 1,045.40% from the latest price.

Price Target

$18.67

(1,045.40% upside)

Analyst Consensus: Buy